Cephalon Looks To Q2 For Launch Of Sparlon
This article was originally published in The Pink Sheet Daily
Executive Summary
Cephalon has pushed back the anticipated launch of its attention deficit/ hyperactivity disorder drug Sparlon (modafinil) from Q1 until the second quarter, pending the outcome of a review by FDA's Psychopharmacologic Drugs Advisory Committee March 23